SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Meredith, P. A
Right arrow Articles by Östergren, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meredith, P. A
Right arrow Articles by Östergren, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies?

Peter A Meredith

Department of Medicine and Therapeutics, Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow, G11 6NT, Scotland, UK, pam1v{at}clinmed.gla.ac.uk

Jan Östergren

Department of Medicine, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden

Although in the developed world the incidence of and mortality from coronary heart disease (CHD) and stroke have been declining over the last 15 years, heart failure is increasing in incidence, prevalence and overall mortality, despite advances in the diagnosis and management of the condition. Hypertension, alone or in combination with CHD, precedes the development of heart failure in the majority of both men and women. Whilst there have been improvements in the overall management of hypertension, as reflected in rates of diagnosis, awareness, treatment and control of blood pressure (BP), there are still many patients with hypertension who remain undiagnosed or untreated and of those who do receive treatment many fail to achieve current targets for BP control. Placebo controlled trials in hypertension, largely based on diuretic and beta-blocker-based regimens, have unequivocally demonstrated that the treatment of hypertension can significantly reduce the incidence of heart failure. Newer treatment strategies offer theoretical and proven practical advantages over established antihypertensive therapy. In particular, AT1-receptor blockers appear to provide benefits beyond BP control and are effective in the treatment of both hypertension and heart failure. Thus, the primary prevention of heart failure in hypertensive patients should be based upon strategies that provide tight and sustained BP control necessitating the use of multiple drugs. However, there is now compelling evidence to suggest that this therapy should include an antihypertensive agent that inhibits the reninangiotensin-aldosterone system (RAAS).

Key Words: Heart failure • Hypertension • Renin-angiotensin-aldosterone system • AT1-receptor blockers • Atrial fibrillation • New-onset diabetes

References

  • Murray CJL, Lopez AD Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Petersen S., Peto V., Rayner M., Leal J., Luengo-Fernandez R., Gray A. European cardiovascular disease statistics. British Heart Foundation: London 2005. Available at http://www.heartstats.org/uploads/documents%5CPDF.pdf
  • Thom T., Haase N., Rosamond W. et al. Heart Disease and Stroke Statistics -2006 Update: A report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation available at http://www.circulationaha.org
  • McKee PA, Castelli WP, McNamara PM, Kannel WB The natural history of congestive heart failure: the Framingham Heart Study. N Engl J Med 1971;285:1441-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Eriksson H., Svardsudd K., Larsson B. et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 1989;10:647-56.[Abstract/Free Full Text]
  • Yusuf S., Abbott RA Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989;13(suppl 1):I-74-I-79.[Medline] [Order article via Infotrieve]
  • Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. Am J Coll Cardiol 1993; 32(suppl A): 6A-13A.
  • Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime Risk for Developing Congestive Heart Failure: the Framingham Heart Study. Circulation 2002;106:3068-72.[Abstract/Free Full Text]
  • Levy D., Larson MG, Martin G., Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.[Abstract/Free Full Text]
  • Wolf-Maier K. Cooper RS Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289(18):2363-9.[Abstract/Free Full Text]
  • Kearney PM, Whelton M., Reynolds K., Muntner P., Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.[Web of Science][Medline] [Order article via Infotrieve]
  • Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med 1996;156(16):1789-96.[Abstract/Free Full Text]
  • Himmelman A. Hypertension: an important precursor of heart failure. Blood Pressure 1999;8:253-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Croft JB, Giles WH, Pollard RA et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505-10.[Abstract/Free Full Text]
  • Levy D., Garrison RJ, Savage DD et al. Left ventricular mass as incidence of coronary heart disease in an elderly cohort: the Framingham study. Ann Intern Med 1989;110:101-07.[Abstract/Free Full Text]
  • Kannel WB, Wolf PA, Garrison RJ (eds). Some risk factors related to the annual incidence of cardiovascular disease and death in pooled, repeated biennial measurements: Framingham Heart Study, 30-year follow-up. Bethesda, MD: National Institutes of Health; 1987:section 34. Publication NIH 87-2703.
  • Weber KT, Brilla CG, Campbell SE, Zhou G., Matsubara L., Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992;1:75-85.[Medline] [Order article via Infotrieve]
  • Lawes CM, Rodgers A., Bennett DA et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21(4):707-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lewington S. Clarke R. Qizilbash N. Peto R. Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nolan SE, Mannisi JA, Bush DE, Healy B., Weismann HF Increased afterload aggravates infarct expansion after acute myocardial infarction. J Am Coll Cardiol 1988;12:1318-25.[Abstract]
  • Nishikimi T., Yamagashi H., Takeuchi K., Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995;29:856-61.[Abstract/Free Full Text]
  • Richards AM, Nichols G., Troughton RW et al. Antecedent hypertension and heart failure after myocardial infarction. JACC 2002; 39(7):1182-8.[Abstract/Free Full Text]
  • Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kostis JB, Davis BR, Cutler J. et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997;278(3):212-16.[Abstract/Free Full Text]
  • Moser M., Herbert PR Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. JACC 1996;27(5):121 R 4-18.[Medline] [Order article via Infotrieve]
  • Marques-Vidal P., Tuomilehto J. Hypertension awareness, treatment and control in the community: is the `rule of halves' still valid? J Hum Hypertens 1997;11:213-20. O[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Primatesta P., Brookes M., Poulter NR Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001;38:827-32.
  • Meissner I., Whisnant JP, Sheps SG et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999;34:466-71.[Abstract/Free Full Text]
  • Weinehall L., Öhgren B., Persson M. et al. High remaining risk in poorly treated hypertension: the `rule of halves' still exists. J Hypertens 2002;20(10):2081-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Conlin PR, Gerth WC, Fox J., Roehm JB Boccuzzi SJ Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics 2001;23(12):1999-2010.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hasford J., Mimran A., Simons WR A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Verdecchia P., Angeli F., Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analvsis. Am J Hypertens 2003;16:895-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.[Web of Science][Medline] [Order article via Infotrieve]
  • Cruickshank J., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy of different types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.[Web of Science][Medline] [Order article via Infotrieve]
  • Liebson PR, Grandits GA, Dianzumba S. et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment Of Mild Hypertension Study (TOMHS). Circulation 1995;91:698-706.[Abstract/Free Full Text]
  • Klingbeil AU, Schneider M., Martus P., Messerli FH, Schmieder RE A meta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am J Med 2003;115:41-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malmqvist K., Kahan T., Edner M. et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cuspidi C., Muiesan ML, Valagussa L. et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension in treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20(11):2293-300.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Krahn AD, Manfreda J., Tate RB, Mathewson FA, Cuddy TE The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
  • Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.[Abstract/Free Full Text]
  • Whelton PK Epidemiology of hypertension. Lancet 1994;344:101-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wilhelmsen L., Rosengren A., Eriksson H., Lappas G. Heart failure in the general population of men -morbidity, risk factors and prognosis. J Intern Med 2001;249:253-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pedersen OD, Bagger H., Kober L., Torp-Pederson C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.[Abstract/Free Full Text]
  • Vermes E., Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-31.[Abstract/Free Full Text]
  • Madrid AH, Bueno MG, Rebollo JMG et al. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A Prospective and Randomized Study. Circulation 2002;106:331-6.[Abstract/Free Full Text]
  • Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. JACC 2005;45(5):712-19.[Abstract/Free Full Text]
  • Wachtell K., Hornestam B., Lehto M. et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. JACC 2005;45(5):705-11.[Abstract/Free Full Text]
  • Ducharme A., Swedberg K., Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the CHARM Program. Am Heart J 2006;152:86-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bell SH Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26(8):2433-41.[Abstract/Free Full Text]
  • Amato L., Paolisso G., Cacciatore F. et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly: the Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997;23:213-18.[Web of Science][Medline] [Order article via Infotrieve]
  • Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10.[Web of Science][Medline] [Order article via Infotrieve]
  • Abuissa H., Jones PG, Marso SP, O'Keefe JH Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. JACC 2005;46(5):821-6.[Abstract/Free Full Text]
  • Yusuf S., Ostergren JB, Gerstein HC et al. on behalf of the Candesartan in Heart Failure - Assessment of reduction in mortality and morbidity program (CHARM) Investigators. Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients with Heart Failure. Circulation 2005;112:48-53.[Abstract/Free Full Text]
  • Carr AA, Kowey PR, Devereux RB et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE Studies. Am J Cardiol 2005;96:1530-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bptllc. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Julius S., Kjeldsen SE, Weber M. et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlof B., Sever PS, Poulter NR et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavia Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study. ELITE II. Lancet 2000; 355(9215):1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • Granger CB, McMurray J., Yusuf S. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet 2003;362:767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McMurray J., Ostergren J., Swedberg K. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet 2003;362:772-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S., Pfeffer M., Swedberg K. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and left ventricular ejection fraction above 40%: the CHARM-Preserved Trial. Lancet 2003;362:777-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer M., Swedberg K., Granger CB et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall Programme. Lancet 2003;362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 2, 64-73 (2006)
DOI: 10.3317/jraas.2006.012
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. J. Postma and D. de Zeeuw
The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 2975 - 2983.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
L. S.M. Wong, R. A. de Boer, N. J. Samani, D. J. van Veldhuisen, and P. van der Harst
Telomere biology in heart failure
Eur J Heart Fail, November 1, 2008; 10(11): 1049 - 1056.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Meredith, P. A
Right arrow Articles by Östergren, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meredith, P. A
Right arrow Articles by Östergren, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement